| 20.02 -1.15 (-5.43%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.36 |
1-year : | 33.33 |
| Resists | First : | 25.14 |
Second : | 28.54 |
| Pivot price | 22.93 |
|||
| Supports | First : | 19.63 |
Second : | 16.34 |
| MAs | MA(5) : | 21.22 |
MA(20) : | 23.69 |
| MA(100) : | 27.5 |
MA(250) : | 32.99 |
|
| MACD | MACD : | -1.8 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 12.2 |
| RSI | RSI(14): 24.5 |
|||
| 52-week | High : | 47.47 | Low : | 19.63 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NTLA ] has closed above bottom band by 10.7%. Bollinger Bands are 29.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.7 - 20.83 | 20.83 - 20.92 |
| Low: | 19.35 - 19.51 | 19.51 - 19.63 |
| Close: | 19.81 - 20.05 | 20.05 - 20.22 |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? - Zacks Investment Research
Thu, 25 Apr 2024
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline - Yahoo Finance
Mon, 22 Apr 2024
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Canada Shine On
Fri, 19 Apr 2024
First Week of June 21st Options Trading For Intellia Therapeutics (NTLA) - Nasdaq
Mon, 01 Apr 2024
Intellia Therapeutics (NASDAQ:NTLA) investors are sitting on a loss of 66% if they invested three years ago - Simply Wall St
Tue, 19 Mar 2024
Intellia Therapeutics doses first patient in pivotal in vivo CRISPR trial - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 96 (M) |
| Held by Insiders | 9.453e+007 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 12,620 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.0632e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 7 % |
| Return on Assets (ttm) | 297.4 % |
| Return on Equity (ttm) | -22.9 % |
| Qtrly Rev. Growth | 3.627e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -23.39 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -394 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.2 |
| Price to Book value | 0 |
| Price to Sales | -0.86 |
| Price to Cash Flow | 3.19 |
| Dividend | 0 |
| Forward Dividend | 1.483e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|